journal article·2022-12Open access

A decade's worth of impact: Dox loaded liposomes in anticancer activity

Puja Ghosh, Himja Tiwari, Jaya Lakkakula, Arpita Roy, Talha Bin Emran, Summya Rashid, Saad Alghamdi, Bodour S. Rajab, Mazen Almehmadi, Mamdouh Allahyani, Abdulelah Aljuaid, Ahad Amer Alsaiari, Rohit Sharma, Ahmad O. Babalghith

Abstract

Clinically approved therapeutics associated with cancer are limited to mostly chemotherapy, surgery and radiotherapy in spite of the advancements in the biomedical field. Due to the cardiotoxicity and uncountable side effects brought by the prevailing treatment strategies, demands are growing for targeted drug delivery using nanomaterials. For this the most commonly used drug, doxorubicin (DOX) is encapsulated within several type of nanovesicles to observe their anticancer activity. Among them, DOX encapsulated liposomes gained popularity because of their clinical success and lower toxicity. To enhance their efficiency and site specific delivery, attempts are made to modify the liposomes by combining them with peptides, aptamers, antibodies etc to develop pH, thermal, UV-sensitive and electro-magnetic liposomal nanocarriers for controlled drug release. The novel strategies for the treatment of Breast, Lung, Liver, Pancreatic, Prostate, Ovarian, Cervical, Blood, Brain and Colon cancer using modified liposomes encapsulating DOX are illustrated in this review.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics · RNA Interference and Gene Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (100+)

Show source-provided references
1. Perspectives and advancements in the design of nanomaterials for targeted cancer theranostics10.1016/j.cbi.2020.109221 ↗
2. An overview of doxorubicin formulations in cancer therapy10.4103/0973-1482.139267 ↗
3. Smart nanocarrier-based drug delivery systems for cancer therapy and toxicity studies: a review
4. A critical review of lipid-based nanoparticles for taxane delivery10.1016/j.canlet.2012.07.006 ↗
5. Recent progress of dendrimers in drug delivery for cancer therapy10.22159/ijap.2018v10i5.27075 ↗
6. Carbon nanotubes as cancer therapeutic carriers and mediators10.2147/IJN.S112660 ↗
7. Application of quantum dots-based biotechnology in cancer diagnosis: current status and future perspectives
8. Folic acid-CdTe quantum dot conjugates and their applications for cancer cell targeting10.1007/s12645-010-0003-3 ↗
9. Screening of specific peptide binding to esophageal squamous carcinoma cells from phage displayed peptide library10.1016/j.mcp.2015.04.001 ↗
10. Advances of metal organic frameworks in analytical applications
11. X-ray induced photodynamic therapy with copper cysteamine nanoparticles in mice tumors10.1073/pnas.1900502116 ↗
12. Active targeting of nano-photosensitizer delivery systems for photodynamic therapy cancer stem cells
13. Colorectal liver metastasis: molecular mechanism and interventional therapy10.1038/s41392-022-00922-2 ↗
14. 2-Hydroxyoleic acid-inserted liposomes as a multifunctional carrier of anticancer drugs10.1080/10717544.2017.1388452 ↗
15. Multiscale kinetic modeling of liposomal Doxorubicin delivery quantifies the role of tumor and drug-specific parameters in local delivery to tumors10.1038/psp.2012.16 ↗
16. Liposomes in drug delivery: progress and limitations10.1016/S0378-5173(97)00135-X ↗
17. Enhanced drug delivery in rabbit VX2 tumours using thermosensitive liposomes and MRI-controlled focused ultrasound hyperthermia
18. Multifunctional liposome nanocarriers combining upconverting nanoparticles and anticancer drugs10.1021/acs.jpcb.6b02013 ↗
19. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma10.1002/cncr.10201 ↗
20. pegylated liposomal doxorubicin in patients with metastatic triple-negative breast cancer: 8-year experience of a single center10.1186/s43046-020-00034-4 ↗
21. PEGylated liposomal doxorubicin rechallenge following doxorubicin-induced pancreatitis
22. Improved drug delivery and therapeutic efficacy of PEgylated liposomal doxorubicin by targeting anti-HER2 peptide in murine breast tumor model10.1016/j.ejps.2016.03.009 ↗
23. pegylated liposomal formulation of doxorubicin overcomes drug resistance in a genetically engineered mouse model of breast cancer10.1016/j.jconrel.2017.07.010 ↗
24. Enhanced binding and killing of target tumor cells by drug-loaded liposomes modified with tumor-specific phage fusion coat protein10.2217/nnm.10.30 ↗
25. Layer-by-layer assembly of liposomal nanoparticles with PEGylated polyelectrolytes enhances systemic delivery of multiple anticancer drugs10.1016/j.actbio.2014.08.021 ↗
26. Substituting Doxorubicin with nonpegylated liposomal Doxorubicin for the treatment of early breast cancer: results of a retrospective study10.1155/2014/984067 ↗
27. The polyethyleneglycol dilemma: advantage and disadvantage of PEGylation of liposomes for systemic genes and nucleic acids delivery to tumors10.1248/bpb.b13-00059 ↗
28. Conditional internalization of PEGylated nanomedicines by PEG engagers for triple negative breast cancer therapy10.1038/ncomms15507 ↗
29. Dual complementary liposomes inhibit triple-negative breast tumor progression and metastasis10.1126/sciadv.aav5010 ↗
30. Co-delivery of doxorubicin and P-gp inhibitor by a reduction-sensitive liposome to overcome multidrug resistance, enhance anti-tumor efficiency and reduce toxicity10.3109/10717544.2014.990651 ↗
31. Preparation and evaluation of liposomes Co-loaded with doxorubicin, phospholipase D inhibitor 5-fluoro-2-indolyl Deschlorohalopemide (FIPI) and D-alpha tocopheryl acid succinate (α-TOS) for anti-metastasis10.1186/s11671-019-2964-4 ↗
32. Remote loading paclitaxel–doxorubicin prodrug into liposomes for cancer combination therapy10.1016/j.apsb.2020.04.011 ↗
33. Mannose modified co-loaded zoledronic liposomes deplete M2-tumor-associated macrophages to enhance anti-tumor effect of doxorubicin on TNBC
34. Tumor microenvironment activated membrane fusogenic liposome with speedy antibody and doxorubicin delivery for synergistic treatment of metastatic tumors10.1021/acsami.6b14683 ↗
35. Enhanced anticancer efficacy by ATP-mediated liposomal drug delivery10.1002/anie.201400268 ↗
36. pH-Sensitive liposomes-principle and application in cancer therapy10.1211/jpp.59.4.0001 ↗
37. Hyaluronic acid modified pH-sensitive liposomes for targeted intracellular delivery of doxorubicin10.3109/08982104.2015.1117489 ↗
38. Drug delivery: gel-liposome-mediated Co-delivery of anticancer membrane-associated proteins and small-molecule drugs for enhanced therapeutic efficacy
39. Combination therapy with liposomal doxorubicin and liposomal vaccine containing E75, an HER-2/neu-derived peptide, reduces myeloid-derived suppressor cells and improved tumor therapy10.1016/j.lfs.2020.117646 ↗
40. Cell penetrating peptide amphiphile integrated liposomal systems for enhanced delivery of anticancer drugs to tumor cells10.1039/c3fd00058c ↗
41. Cell-targeting and cell-penetrating peptides for delivery of therapeutic and imaging agents
42. Legumain protease-activated TAT-liposome cargo for targeting tumours and their microenvironment10.1038/ncomms5280 ↗
43. Ferri-liposomes as an MRI-visible drug-delivery system for targeting tumours and their microenvironment10.1038/nnano.2011.112 ↗
44. Folate-coated, long-circulating and pH-sensitive liposomes enhance doxorubicin antitumor effect in a breast cancer animal model
45. Estrogen-anchored pH-sensitive liposomes as nanomodule designed for site-specific delivery of doxorubicin in breast cancer therapy10.1021/mp200439z ↗
46. Mechanistic insights into the intracellular release of doxorubicin from pH-sensitive liposomes
47. Targeted tumor cell internalization and imaging of multifunctional quantum dot-conjugated immunoliposomes in vitro and in vivo10.1021/nl801488u ↗
48. Liposomal nanotheranostics for multimode targeted in vivo bioimaging and near-infrared light mediated cancer therapy10.1038/s42003-020-1016-z ↗
49. Nanobowl-supported liposomes improve drug loading and delivery10.1021/acs.nanolett.0c00495 ↗
50. Functional evaluation of doxorubicin decorated polymeric liposomal curcumin: a surface tailored therapeutic platform for combination chemotherapy10.1039/C8NJ02406E ↗
51. The emerging treatment landscape of targeted therapy in non-small-cell lung cancer10.1038/s41392-019-0099-9 ↗
52. Torre · Adv. Exp. Med. Biol. · 2016 · 893 · 110.1007/978-3-319-24223-1_1 ↗
53. 50 Years of progress in the systemic therapy of non-small cell lung cancer. American Society of Clinical Oncology educational book. American Society of Clinical Oncology
54. Fabrication of liposomal doxorubicin exhibiting ultrasensitivity against phospholipase A2 for efficient pulmonary drug delivery to lung cancers10.1016/j.ijpharm.2016.11.039 ↗
55. Fusogenic liposomes as nanocarriers for the delivery of intracellular proteins10.1021/acs.langmuir.6b04304 ↗
56. A nanoparticle-based combination chemotherapy delivery system for enhanced tumor killing by dynamic rewiring of signaling pathways10.1126/scisignal.2005261 ↗
57. Synthesis of defined oligohyaluronates-decorated liposomes and interaction with lung cancer cells10.1016/j.carbpol.2020.116798 ↗
58. Layer-by-layer pH-sensitive nanoparticles for drug delivery and controlled release with improved therapeutic efficacy in vivo10.1080/10717544.2019.1709922 ↗
59. Selenium-functionalized liposomes for systemic delivery of doxorubicin with enhanced pharmacokinetics and anticancer effect10.1016/j.ejpb.2017.10.010 ↗
60. Superselective drug delivery using doxorubicin-encapsulated liposomes and ultrasound in a mouse model of lung metastasis activation10.1016/j.ultrasmedbio.2018.04.003 ↗
61. Concurrent administration of Docetaxel and Stealth liposomal doxorubicin with radiotherapy in non-small cell lung cancer : excellent tolerance using subcutaneous amifostine for cytoprotection10.1038/sj.bjc.6600486 ↗
62. Targeted chemotherapy for subcutaneous and orthotopic non-small cell lung tumors with cyclic RGD-functionalized and disulfide-crosslinked polymersomes doxorubicin10.1038/s41392-018-0032-7 ↗
63. Comprehensive review of targeted therapy for colorectal cancer10.1038/s41392-020-0116-z ↗
64. Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors
65. Asiatic acid enhances intratumor delivery and the antitumor effect of pegylated liposomal doxorubicin by reducing tumor-stroma collagen10.1038/s41401-018-0038-2 ↗
66. Author Correction: liposomal formulation of Galbanic acid improved therapeutic efficacy of pegylated liposomal Doxorubicin in mouse colon carcinoma10.1038/s41598-020-60918-2 ↗
67. Anti-angiogenic and anti-inflammatory effects of long-circulating liposomes co-encapsulating curcumin and doxorubicin on C26 murine colon cancer cells10.1016/j.pharep.2017.10.004 ↗
68. Anti-epcam aptamer (Syl3c)-Functionalized liposome for targeted delivery of doxorubicin: in vitro and in vivo antitumor studies in mice bearing C26 colon carcinoma10.1186/s11671-020-03334-9 ↗
69. Chemo-immunotherapy of colon cancer with focused ultrasound and Salmonella-laden temperature sensitive liposomes (thermobots)10.1038/s41598-018-30106-4 ↗
70. Cancer antineovascular therapy with liposome drug delivery systems targeted to BiP/GRP7810.1002/ijc.25276 ↗
71. α-Enolase-binding peptide enhances drug delivery efficiency and therapeutic efficacy against colorectal cancer10.1126/scitranslmed.aaa9391 ↗
72. Magnetic liposomes for colorectal cancer cells therapy by high-frequency magnetic field treatment10.1186/1556-276X-9-497 ↗
73. Controlled gene and drug release from a liposomal delivery platform triggered by X-ray radiation10.1038/s41467-018-05118-3 ↗
74. Tumour evolution in hepatocellular carcinoma10.1038/s41575-019-0229-4 ↗
75. Cationic polymethacrylate-modified liposomes significantly enhanced doxorubicin delivery and antitumor activity
76. Poly(γ-glutamic acid)-coated lipoplexes loaded with Doxorubicin for enhancing the antitumor activity against liver tumors10.1186/s11671-017-2081-1 ↗
77. Doxorubicin and Lovastatin co-delivery liposomes for synergistic therapy of liver cancer
78. Enhanced anticancer effect of doxorubicin by TPGS-coated liposomes with Bcl-2 siRNA-corona for dual suppression of drug resistance
79. Theranostic liposomes as nanodelivered chemotherapeutics enhanced the microwave ablation of hepatocellular carcinoma10.2217/nnm-2018-0424 ↗
80. Improved efficacy of doxorubicin delivery by a novel dual-ligand-modified liposome in hepatocellular carcinoma10.1016/j.canlet.2020.06.017 ↗
81. Endogenous tumor microenvironment-responsive multifunctional nanoplatforms for precision cancer theranostics10.1016/j.ccr.2020.213529 ↗
82. MiR-101 and doxorubicin codelivered by liposomes suppressing malignant properties of hepatocellular carcinoma10.1002/cam4.1016 ↗
83. Cervical cancer, different treatments and importance of bile acids as therapeutic agents in this disease10.3389/fphar.2019.00484 ↗
84. New pH-responsive gemini lipid derived co-liposomes for efficacious doxorubicin delivery to drug resistant cancer cells10.1039/C7CC03320F ↗
85. Near-infrared-triggered azobenzene-liposome/upconversion nanoparticle hybrid vesicles for remotely controlled drug delivery to overcome cancer multidrug resistance10.1002/adma.201503799 ↗
86. A multifunctional liposomal nanoplatform co-delivering hydrophobic and hydrophilic doxorubicin for complete eradication of xenografted tumors10.1039/C9NR04669K ↗
88. Intracellular delivery of drugs by chitosan-based multi-liposomal complexes10.1016/j.colsurfb.2020.111062 ↗
89. A dual-channel endoscope for quantitative imaging, monitoring, and triggering of doxorubicin release from liposomes in living mice10.1038/s41598-017-15790-y ↗
90. Protein tyrosine phosphatase PTPN3 promotes drug resistance and stem cell-like characteristics in ovarian cancer
91. Liposome-encapsulated doxorubicin citrate in previously treated recurrent/metastatic gynecological malignancies10.1111/j.1525-1438.2007.00825.x ↗
92. Ge · Epigenetic modulations and lineage plasticity in advanced prostate cancer. Annals of oncology : official journal of the European Society for Medical Oncology · 2020 · 31 · 470
93. Oncogenic and tumor suppressive microRNAs in prostate cancer10.1016/j.coemr.2020.02.002 ↗
94. Comparison of drug delivery efficiency between doxorubicin intercalated in RNA aptamer and one encapsulated in RNA aptamer-conjugated liposome
95. Towards a multiphysics modelling framework for thermosensitive liposomal drug delivery to solid tumour combined with focused ultrasound hyperthermia10.1007/s41048-019-0083-5 ↗
96. Hyperthermia-induced doxorubicin delivery from thermosensitive liposomes via MR-HIFU in a pig model10.1016/j.jconrel.2022.02.003 ↗
97. Skin cancer and new treatment perspectives: a review10.1016/j.canlet.2014.11.001 ↗
98. Melanoma treatment in review10.2147/ITT.S134842 ↗
99. Intracellular delivery of doxorubicin with RGD-modified sterically stabilized liposomes for an improved antitumor efficacy: in vitro and in vivo10.1002/jps.20397 ↗
100. MRI monitoring of tumor-selective anticancer drug delivery with stable thermosensitive liposomes triggered by high-intensity focused ultrasound. Molecular pharmaceutics10.1021/acs.molpharmaceut.6b00013 ↗